Structure

TOLNAFTATE (>98%)

CAS
2398-96-1
Catalog Number
ALC-FP-2398961
Category
Featured Products
Molecular Weight
307.41 g/mol
Molecular Formula
C19H17NOS

If you have any other questions or need other size, please get a quote.

  • Product Description
  • Case Study
  • Custom Reviews
  • Custom Q&A
  • Synthetic Use
  • Related Resources

Specification

Melting Point
110.0-113.0°C
Appearance
White or Light Yellow Powder
Assay
98.0 - 102.0%
Heavy Metal
≤ 0.002%
Ignition Residue
≤ 0.1%
Drying Loss
≤ 0.5%
Sample Lot No.
20240305HJ

Tolnaftate for Experimental Inhibition of Ergosterol Biosynthesis in Leishmania spp.

Tolnaftate inhibits ergosterol production and impacts cell viability of Leishmania sp. Yamamoto ES, et al. Bioorganic Chemistry, 2020, 102, 104056.

Tolnaftate was experimentally evaluated as an antileishmanial agent targeting sterol metabolism in Leishmania spp. Promastigote forms of L. amazonensis, L. braziliensis, and L. infantum were cultured in vitro and treated with graded concentrations of tolnaftate to determine leishmanicidal activity, with EC₅₀ values quantified via cell viability assays. Intracellular amastigote assays were conducted using infected macrophages to assess efficacy under physiologically relevant conditions and calculate selectivity indices. To elucidate the mechanism of action, parasites treated at EC₅₀ concentrations underwent ultrastructural analysis, revealing mitochondrial and membrane alterations. Ergosterol content was quantified following drug exposure, demonstrating a marked reduction consistent with squalene epoxidase inhibition. These experimental results confirm tolnaftate's functional application as a sterol biosynthesis inhibitor, directly linking enzymatic blockade to membrane disruption and parasite death in Leishmania models.

Please kindly note that our products are for research use only.

Alfa Chemistry

For product inquiries, please use our online system or send an email to .

Alfa Chemistry
Shopping basket
Loading...
Loading...
Download PDF documentDownload
* I hereby give my consent that I may receive marketing e-mails with information on existing and new services from this company. I know that I can opt-out from receiving such e-mails at any time or by using the link which will be provided in each marketing e-mail.